INKT: MiNK Net earnings per share (EPS TTM)

MiNK Therapeutics (INKT) - corporate logo

MiNK Therapeutics, Inc. (INKT) operates in a cash-burn mode for research, which precludes profit predictability. The rolling annual earnings per share chart visualizes this process, where the -2.25 level indicates the parameter's status. Business results are independent of the economy and instead depend on testing phases. Expected T-cell data will serve as key drivers for share price growth.

INKT MiNK Therapeutics, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for MiNK Therapeutics, Inc (INKT)

- share price and expert price forecast:
Fundamental valuation:INKT - MiNK Therapeutics, Inc
Flagship merchandise of MiNK

This indicator reflects the net income distributed per common share over the last four quarters. The calculation is based on the company's bottom-line profit minus all expenses and taxes, divided by the total number of securities. By analyzing the rolling annual earnings per share, an investor assesses the actual efficiency of capital generation. For MiNK Therapeutics, Inc. (INKT), this metric demonstrates financial stability while developing innovative iNKT therapies. The brand's scientific reputation in immuno-oncology directly influences the long-term trajectory of this metric.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)